Assessing Combined Bevacizumab-Mitomycin C Use During Ahmed Valve Revision in Recurrent Pediatric Glaucoma

Early Phase 1CompletedNCT06983704

Benha University50 enrolled

Overview

To asess the efficacy and safety of combining subconjunctival bevacizumab with mitomycin C (MMC) during AGV revision surgery in pediatric patients with recurrent glaucoma.

Recurrent pediatric glaucoma following Ahmed Glaucoma Valve (AGV) implantation presents a therapeutic challenge. This study evaluates the efficacy and safety of combining subconjunctival bevacizumab with mitomycin C (MMC) during AGV revision surgery in pediatric patients with recurrent glaucoma.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

SINGLE

Enrollment

Conditions

Pediatric Glaucoma

Interventions

AGV platePROCEDURE

AGV plate using a 27-gauge needle

bevacizumab injectionPROCEDURE

subconjunctival injection of bevacizumab

Eligibility

Sex: ALLMax age: 12 Years

Medical Language ↔ Plain English

Inclusion Criteria: * children under 12 years with previous AGV implantation for primary congenital glaucoma Exclusion Criteria: * age \>12 years, eyes with no light perception, and those with prior cyclodestructive procedures.

Locations (1)

Al-Azhar University

Cairo, Egypt

Outcomes

Primary Outcomes

surgical success

IOP ≤ 21 mmHg and ≥ 5 mmHg without medications

Time frame: for 12 months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.